WASHINGTON — A Pfizer drug, Lorlatinib, has shown significant efficacy in reducing tumor progression and improving survival rates for patients in the advanced stages of…
WASHINGTON — A Pfizer drug, Lorlatinib, has shown significant efficacy in reducing tumor progression and improving survival rates for patients in the advanced stages of…